查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1586181

细胞再程式化市场：按技术、应用和最终用途划分 – 2025-2030 年全球预测

Cell Reprogramming Market by Technology (Episomal Reprogramming, mRNA Reprogramming, Sendai Virus-Based Reprogramming), Application (Research, Therapeutic), End-Use - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

细胞再程式化市场2023年估值为3.7559亿美元，预计到2024年将达到4.1388亿美元，复合年增长率为10.59%，到2030年将达到7.5992亿美元。

细胞再程式化是指将成熟的特化细胞转回具有分化成任何类型细胞能力的多功能细胞的过程。这种创新方法在再生医学和生物技术中具有重要意义，因为它在治疗退化性疾病、组织修復和药物发现方面具有巨大潜力。对 KEYWORD 的需求源于其超越成人和胚胎干细胞使用限制的能力，为研究和治疗应用提供更通用、更合乎道德的替代方案。最终用户包括专注于再生医学和个人化医疗解决方案的製药公司、研究机构和医疗机构。

主要市场统计
基准年[2023] 37559万美元
预测年份 [2024] 41388万美元
预测年份 [2030] 75992万美元
复合年增长率（%） 10.59%

细胞再程式化市场的成长主要是由干细胞研究投资的增加、CRISPR等基因工程技术的进步以及对慢性疾病有效治疗解决方案的持续需求所推动的。组织工程和 3D 生物列印领域的创新正在将再程式化的范围从基础研究扩展到临床环境，创造出令人兴奋的应用。机会在于开发可扩展、高效且安全的初始化技术，克服当前的限制，例如低效率和潜在的基因组不稳定性。建议与领先的生物技术公司和学术机构建立策略伙伴关係和合作，以释放此类机会。

然而，再程式化过程的高成本、道德问题、监管障碍和技术复杂性等限制构成了重大挑战。与基因组修饰相关的潜在安全问题和与多功能细胞相关的肿瘤发展风险也阻碍了市场。应对这些挑战需要集中创新，以提高初始化效率和安全分析，同时确保遵守不断变化的法规。

需要研究和创新的领域包括开发非整合初始化方法、改进直接初始化方法以最小化中间多功能阶段以及增强自动初始化系统的稳健性。随着细胞再程式化市场的成熟，向更有针对性的方法和个性化应用的转变可能会成为其发展的特征，这使其成为擅长应对复杂情况的公司的一项重大投资，并提供了成长潜力。

市场动态：揭示快速发展的细胞再程式化市场的关键市场洞察

细胞再程式化市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 在再生医学和疾病建模的应用
    • 采用尖端技术进行干细胞研究与治疗
    • 药物发现和药物开发活动的增加
  • 市场限制因素
    • 细胞再程式化高成本
  • 市场机会
    • 细胞重编程的进展
    • 对细胞再程式化的重大投资
  • 市场挑战
    • 细胞再程式化的技术问题与局限性

波特五力：驾驭细胞再程式化市场的策略工具

波特的五力框架是了解细胞再程式化市场竞争格局的关键工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解细胞再程式化市场的外部影响

外部宏观环境因素在塑造细胞再程式化市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解细胞再程式化市场的竞争状况

对细胞再程式化市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的见解，以应对日益激烈的竞争。

FPNV定位矩阵单元再程式化市场供应商绩效评估

FPNV定位矩阵是评估细胞再程式化市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议，以规划细胞再程式化市场的成功之路

细胞再程式化市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 在再生医学和疾病模型的应用
      • 引进干细胞研究和治疗的先进技术
      • 增加药物发现和开发活动
    • 抑制因素
      • 细胞再程式化成本高昂
    • 机会
      • 细胞再程式化的进展
      • 对细胞再程式化的重大投资
    • 任务
      • 细胞再程式化的技术问题与局限性
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章细胞再程式化市场：依技术分类

  • 游离重编程
  • mRNA重编程
  • 用仙台病毒重新编程

第七章细胞再程式化市场：依应用分类

  • 调查
  • 治疗性的

第八章细胞再程式化市场：依最终用途

  • 生物技术和製药公司
  • 医院/诊所
  • 研究/学术机构

第九章美洲细胞再程式化市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太细胞再程式化市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲细胞再程式化市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • ALSTEM Inc.
  • Applied Biological Materials Inc.
  • Axol Bioscience Ltd.
  • Bit Bio Ltd.
  • Bristol Myers Squibb Company
  • CD Biosynsis
  • Cell Reprogramming & Therapeutics LLC
  • Cellular Reprogramming, Inc.
  • Creative Bioarray
  • DefiniGEN Limited
  • Fujifilm LImited
  • Lonza AG
  • Merck KGaA
  • Mogrify Limited
  • REPROCELL Inc.
  • Stemnovate Limited
  • Takara Bio Inc.
  • Thermo Fisher Scientific, Inc.
  • TOKIWA-Bio inc.,
  • Allele Biotechnology and Pharmaceuticals, Inc.
Product Code: MRR-F927BA462855

The Cell Reprogramming Market was valued at USD 375.59 million in 2023, expected to reach USD 413.88 million in 2024, and is projected to grow at a CAGR of 10.59%, to USD 759.92 million by 2030.

Cell reprogramming refers to the process of reverting mature, specialized cells into pluripotent stem cells, which have the ability to differentiate into any cell type. This innovative approach is crucial in regenerative medicine and biotechnology due to its vast potential for treating degenerative diseases, tissue repair, and drug discovery. The necessity for cell reprogramming arises from its ability to transcend the limitations of adult stem cells and embryonic stem cell use, providing a more versatile and ethical alternative for research and therapeutic applications. End-users span pharmaceutical companies, research laboratories, and medical institutions focusing on regenerative medicine and personalized healthcare solutions.

KEY MARKET STATISTICS
Base Year [2023] USD 375.59 million
Estimated Year [2024] USD 413.88 million
Forecast Year [2030] USD 759.92 million
CAGR (%) 10.59%

Market growth for cell reprogramming is primarily driven by increasing investments in stem cell research, advancements in genetic engineering technologies such as CRISPR, and the ongoing demand for efficient treatment solutions for chronic conditions. Innovations in tissue engineering and 3D bioprinting are creating exciting applications, expanding the reprogramming scope beyond basic research into potential clinical environments. Opportunities lie in developing scalable, efficient, and safe reprogramming techniques that overcome current limitations such as low efficiency and potential genomic instability. Strategic partnerships and collaborations with leading biotech firms and academic institutions are recommended to unlock these opportunities.

However, limitations such as high costs, ethical concerns, regulatory hurdles, and the technical complexity of reprogramming processes pose significant challenges. The market is also hindered by potential safety issues related to genomic modifications and the tumorigenic risks associated with pluripotent cells. Addressing these challenges requires focused innovations in enhancing reprogramming efficiency and safety profiling while ensuring compliance with evolving regulations.

Areas ripe for research and innovation include developing non-integrative reprogramming methods, improving direct reprogramming to minimize intermediate pluripotent stages, and enhancing the robustness of automated reprogramming systems. As the cell reprogramming market matures, a shift towards more targeted approaches and personalized applications will likely characterize its evolution, offering substantial growth potential for companies adept at navigating its complexities.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cell Reprogramming Market

The Cell Reprogramming Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Applications in regenerative medicine and disease modeling
    • Adoption of advanced technologies in stem cell research and therapies
    • Rise in drug discovery and drug development activities
  • Market Restraints
    • High cost of cell reprogramming
  • Market Opportunities
    • Advancements in cellular reprogramming
    • Significant investments in cell reprogramming
  • Market Challenges
    • Technical issues and limitations of cell reprogramming

Porter's Five Forces: A Strategic Tool for Navigating the Cell Reprogramming Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cell Reprogramming Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cell Reprogramming Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cell Reprogramming Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cell Reprogramming Market

A detailed market share analysis in the Cell Reprogramming Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cell Reprogramming Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cell Reprogramming Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cell Reprogramming Market

A strategic analysis of the Cell Reprogramming Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cell Reprogramming Market, highlighting leading vendors and their innovative profiles. These include ALSTEM Inc., Applied Biological Materials Inc., Axol Bioscience Ltd., Bit Bio Ltd., Bristol Myers Squibb Company, CD Biosynsis, Cell Reprogramming & Therapeutics LLC, Cellular Reprogramming, Inc., Creative Bioarray, DefiniGEN Limited, Fujifilm LImited, Lonza AG, Merck KGaA, Mogrify Limited, REPROCELL Inc., Stemnovate Limited, Takara Bio Inc., Thermo Fisher Scientific, Inc., TOKIWA-Bio inc.,, and Allele Biotechnology and Pharmaceuticals, Inc..

Market Segmentation & Coverage

This research report categorizes the Cell Reprogramming Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Technology, market is studied across Episomal Reprogramming, mRNA Reprogramming, and Sendai Virus-Based Reprogramming.
  • Based on Application, market is studied across Research and Therapeutic.
  • Based on End-Use, market is studied across Biotechnology & Pharmaceutical Companies, Hospitals & Clinics, and Research & Academic Institutes.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Applications in regenerative medicine and disease modeling
      • 5.1.1.2. Adoption of advanced technologies in stem cell research and therapies
      • 5.1.1.3. Rise in drug discovery and drug development activities
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of cell reprogramming
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in cellular reprogramming
      • 5.1.3.2. Significant investments in cell reprogramming
    • 5.1.4. Challenges
      • 5.1.4.1. Technical issues and limitations of cell reprogramming
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cell Reprogramming Market, by Technology

  • 6.1. Introduction
  • 6.2. Episomal Reprogramming
  • 6.3. mRNA Reprogramming
  • 6.4. Sendai Virus-Based Reprogramming

7. Cell Reprogramming Market, by Application

  • 7.1. Introduction
  • 7.2. Research
  • 7.3. Therapeutic

8. Cell Reprogramming Market, by End-Use

  • 8.1. Introduction
  • 8.2. Biotechnology & Pharmaceutical Companies
  • 8.3. Hospitals & Clinics
  • 8.4. Research & Academic Institutes

9. Americas Cell Reprogramming Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Cell Reprogramming Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Cell Reprogramming Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. ALSTEM Inc.
  • 2. Applied Biological Materials Inc.
  • 3. Axol Bioscience Ltd.
  • 4. Bit Bio Ltd.
  • 5. Bristol Myers Squibb Company
  • 6. CD Biosynsis
  • 7. Cell Reprogramming & Therapeutics LLC
  • 8. Cellular Reprogramming, Inc.
  • 9. Creative Bioarray
  • 10. DefiniGEN Limited
  • 11. Fujifilm LImited
  • 12. Lonza AG
  • 13. Merck KGaA
  • 14. Mogrify Limited
  • 15. REPROCELL Inc.
  • 16. Stemnovate Limited
  • 17. Takara Bio Inc.
  • 18. Thermo Fisher Scientific, Inc.
  • 19. TOKIWA-Bio inc.,
  • 20. Allele Biotechnology and Pharmaceuticals, Inc.

LIST OF FIGURES

  • FIGURE 1. CELL REPROGRAMMING MARKET RESEARCH PROCESS
  • FIGURE 2. CELL REPROGRAMMING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS CELL REPROGRAMMING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS CELL REPROGRAMMING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES CELL REPROGRAMMING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES CELL REPROGRAMMING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC CELL REPROGRAMMING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC CELL REPROGRAMMING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CELL REPROGRAMMING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CELL REPROGRAMMING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. CELL REPROGRAMMING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. CELL REPROGRAMMING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CELL REPROGRAMMING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CELL REPROGRAMMING MARKET DYNAMICS
  • TABLE 7. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY EPISOMAL REPROGRAMMING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY MRNA REPROGRAMMING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY SENDAI VIRUS-BASED REPROGRAMMING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS CELL REPROGRAMMING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES CELL REPROGRAMMING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC CELL REPROGRAMMING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA CELL REPROGRAMMING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 145. CELL REPROGRAMMING MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 146. CELL REPROGRAMMING MARKET, FPNV POSITIONING MATRIX, 2023